Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications

帕博西利布 富维斯特朗 医学 药效学 药理学 癌症 癌症研究 药代动力学 雌激素受体 乳腺癌 内科学 转移性乳腺癌
作者
Liv Johannessen,Shanhu Hu,Nan Rosemary Ke,Anthony D’Ippolito,Nisha Rajagopal,Jason Marineau,Anneli Savinainen,William C. Zamboni,Graeme Hodgson
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:18 (12_Supplement): C091-C091 被引量:9
标识
DOI:10.1158/1535-7163.targ-19-c091
摘要

Abstract Introduction: CDK7 is a key regulator of transcription and cell cycle progression and has been implicated in multiple tumor types driven by aberrant transcriptional control (e.g. MYC-, ESR1-activation) and/or aberrant cell cycle control (e.g. RB1, CCNE1, CDKN2A alterations). SY-5609 is an oral, potent, and highly selective CDK7 inhibitor that is advancing through IND-enabling studies to support initiation of a planned Phase 1 oncology trial in early 2020. Here we report on the relationship between pharmacokinetics (PK), pharmacodynamics (PD), and tumor growth inhibition (TGI) in xenograft models of tumor types with transcriptional and/or cell cycle aberrations including high grade serous ovarian cancer (HGSOC), small cell lung cancer (SCLC), triple negative breast cancer (TNBC), and estrogen receptor positive breast cancer (ER+BC). Methods: The relationship between SY-5609 PK, PD, and TGI was evaluated in xenograft models of HGSOC (OVCAR3) and TNBC (HCC70) using once daily (QD) or twice daily (BID) dosing via oral gavage. SY-5609 TGI was evaluated as a single agent (SA) QD in patient-derived xenograft (PDX) models of HGSOC (n=3), SCLC (n=4), TNBC (n=4), and in combination with once weekly fulvestrant in ER+BC PDX models selected in vivo for resistance to the CDK4/6 inhibitor palbociclib (n=1) or resistance to both palbociclib and fulvestrant (n=1). Results: SY-5609 plasma exposure was dose proportional and did not accumulate after repeated therapeutic doses. Dose-dependent transcriptional responses in xenograft tissue were observed within 4 hours of SY-5609 dosing and were sustained for 24 hours. TGI was dose-dependent, with tumor regressions observed at doses significantly below the maximum tolerated dose (MTD). Similar TGI was seen when the same daily dose was administered either QD or BID suggesting that the effect was driven by overall exposure or minimum concentration. In HGSOC, SCLC, and TNBC PDX models, SA SY-5609 induced >50% TGI in all models tested (11/11), with 7/11 (64%) demonstrating robust anti-tumor activity (≥90% TGI or regression): 3/3 HGSOC, 2/4 SCLC, and 2/4 TNBC. In a palbociclib-resistant ER+BC PDX model, the combination of SY-5609 and fulvestrant induced significant TGI (89%), with no evident tumor regrowth up to 21 days after dosing cessation, distinguishing the observed effects from SY-5609 SA or fulvestrant SA. In a palbociclib and fulvestrant double-resistant ER+ BC PDX model, SY-5609 SA resulted in 33% TGI and fulvestrant SA had no activity. In contrast, the combination of SY-5609 and fulvestrant demonstrated significant TGI (68%; p<0.0001 vs fulvestrant SA), suggesting re-sensitization to fulvestrant. Conclusions: We have characterized PK, PD, and anti-tumor activity of the CDK7 inhibitor SY-5609 in a series of xenograft models. Exposure in plasma is dose-proportional and does not accumulate at therapeutic dose levels. SY-5609 induces dose-dependent transcriptional responses in tumor xenograft tissue and shows robust TGI, including regressions, in PDX models derived from multiple solid tumor indications. These results highlight the broad potential for SY-5609 across a variety of solid tumor types, including treatment resistant ER+BC, and support the development of SY-5609 in early phase clinical trials. Citation Format: Liv H Johannessen, Shanhu Hu, Nan Ke, Anthony D'Ippolito, Nisha Rajagopal, Jason Marineau, Anneli Savinainen, William Zamboni, Graeme Hodgson. Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C091. doi:10.1158/1535-7163.TARG-19-C091

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
炙热觅海发布了新的文献求助10
1秒前
penghui完成签到,获得积分10
2秒前
3秒前
3秒前
英吉利25发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
毛男完成签到,获得积分10
4秒前
期刊的应助被tian采纳,获得10
5秒前
QBS完成签到,获得积分10
5秒前
5秒前
5秒前
丘比特的应助被睡不醒的xx采纳,获得10
7秒前
shw完成签到 ,获得积分10
8秒前
XingjieY完成签到,获得积分10
8秒前
爆米花的应助被macarthur采纳,获得10
8秒前
杏仁豆腐发布了新的文献求助10
9秒前
Z2H完成签到,获得积分10
9秒前
sheey的应助被非洲大象采纳,获得30
9秒前
FIREWORK完成签到,获得积分10
10秒前
完美世界的应助被甄阳采纳,获得10
10秒前
XingjieY发布了新的文献求助10
10秒前
10秒前
科研通AI6.3的应助被pyl采纳,获得10
11秒前
hhh完成签到,获得积分10
11秒前
外向梦山发布了新的文献求助10
11秒前
12秒前
CipherSage的应助被xucc采纳,获得10
12秒前
13秒前
13秒前
14秒前
英姑的应助被大王叫我来巡山采纳,获得10
16秒前
16秒前
南岸南瓜发布了新的文献求助10
17秒前
所所的应助被vv采纳,获得10
17秒前
EVE_AElle_Lee发布了新的文献求助10
17秒前
炙热觅海完成签到,获得积分10
17秒前
wanci的应助被单纯的海安采纳,获得10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175429
求助须知:如何正确求助?哪些是违规求助? 9567162
关于积分的说明 21790896
捐赠科研通 7769976
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556237
邀请新用户注册赠送积分活动 2477281